Construction and expression of adeno-associated virus type-2 vector carrying human telomerase reverse transcriptase in human nucleus pulposus cells

doi:10.3969/j.issn.2095-4344.2014.15.019

Abstract

Abstract:

BACKGROUND: In animal experiments, transplantation of autologous nucleus pulposus cellscan effectively repair the intervertebral disk degeneration. However, nucleus pulposus cells have a poor ability of proliferation in vitro, which limits its application as seed cells in treatment of intervertebral disk disease.
OBJECTIVE: To construct recombinant adeno-associated virus type-2 vector carrying human telomerase reverse transcriptase and observe the human telomerase reverse transcriptase mRNA expression in human nucleus pulposus cells in vitro.
METHODS: After the plasmid pSNAV2.0-pRSV-hTERT was constructed and identified, recombinant adeno-associated virus type-2 vector carrying human telomerase reverse transcriptase were constructed, amplified and purified by AAVMaxTM package and purification system. The optimal multiplicity of infection for human nucleus pulposus cells was detected by recombinant adeno-associated virus type-2 vector carrying enhanced green fluorescent protein. According the optimal multiplicity of infection (5 × 10⁴ v•g/cell), three different multiplicity of infection (1×104, 5×104, 1×105 v•g/cell) of recombinant adeno-associated virus type-2 vector carrying human telomerase reverse transcriptase were determined to transfect the first passage human nucleus pulposus cells in vitro. In control group, the cells were transfected with adeno-associated virus type-2 vector without human telomerase reverse transcriptase. At 1, 2, 4 weeks after transfection, mRNA expression of human telomerase reverse transcriptase in human nucleus pulposus cells were semi-quantitatively detected by RT-PCR.
RESULTS AND CONCLUSION: The recombinant adeno-associated virus type-2 vector carrying human telomerase reverse transcriptase was successfully constructed, and the titer of the obtained vector was more than 2×10¹¹ v•g/mL. The optimal multiplicity of infection was 5×10⁴ v•g/cell. The mRNA expression of human telomerase reverse transcriptase in human nucleus pulposus cells could be detected in different multiplicity of infection (1×10⁴, 5×10⁴, 1×10⁵ v•g/cell). At 2 weeks post-transfection, mRNA expression of human nucleus pulposus cells was the highest (P < 0.05), as detected by semi-quantitative RT-PCR. Moreover, the stable and high mRNA expression of human telomerase reverse transcriptase could be detected at 4 weeks post-transfection. In control group, no human telomerase reverse transcriptase mRNA expression was found. The recombinant adeno-associated virus type-2 vector carrying human telomerase reverse transcriptase can be successfully constructed, and can mediate a stable mRNA expression of human telomerase reverse transcriptase in human nucleus pulposus cells. Our findings provide a novel strategy of enhancing the properties of nucleus pulposus cells.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

全文链接：

Key words: gene, transfection, tolemere, polymerase chain reaction

CLC Number:

R318

Sun Jie, Pan Zhi-qiang, Zhu Yue-liang, Zhou Tian-hua. Construction and expression of adeno-associated virus type-2 vector carrying human telomerase reverse transcriptase in human nucleus pulposus cells[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(15): 2409-2414.

Figures/Tables 5

References

[1]Meisel HJ, Siodla V, Ganey T, et al. Clinical experience in cell-based therapeutics: disc chondrocyte transplantation A treatment for degenerated or damaged intervertebral disc. Biomol Eng. 2007;24(1):5-21.
[2]Halloran DO, Grad S, Stoddart M, et al. An injectable cross-linked scaffold fornucleus pulposus regeneration. Biomaterials. 2008;29(4):438-447.
[3]Campisi J, Sahn-Ho K, Chang-Su L, et al. Cellular senescence，cancer and aging；the telomere connection.Exp Gerontol. 2001;36:1619.
[4]Greider CW. Telomere length regulation. Annu Rev Biochem. 1996;65:337.
[5]Blackburn EH. Telomere states and cell fates. Nature. 2000; 408(6808):53-56.
[6]Yan P, Bosman FT, Benhattar J. Tissue quanlity is an important determinant of telomerase activity as measured by TRAP assay. Biotechniques. 1998;25(4):660-662.
[7]Wieser M, Stadler G, Jennings P, et al. hTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics. Am J Physiol Renal Physiol. 2008;295(5):F1365-1375.
[8]Lee KM, Choi KH, Ouellette MM. Use of exogenous hTERT to immortalize primary human cells. Cytotechnology. 2004; 45(1-2):33-38.
[9]Gao K, Lu YR, Wei LL, et al. Immortalization of mesenchymal stem cells from bone marrow of rhesus monkey by transfection with human telomerase reverse transcriptase gene. Transplant Proc. 2008;40(2):634-637.
[10]Chung SA, Wei AQ, Connor DE, et al. Nucleus pulposus cellular longevity by telomerase gene therapy, Spine. 2007; 32(11):1188-1196.
[11]Matsumura T, Takesue M, Westerman KA, et al. Establishment of an immortalized human-liver endothelial cell line with SV40T and hTERT. Transplantation. 2004; 77(9):1357-1365.
[12]Wei LL, Gao K, Liu PQ, et al. Mesenchymal stem cells from Chinese Guizhou minipig by hTERT gene transfection, Transplant Proc. 2008;40(2):547-550.
[13]Sakai D, Mochida J, Yamamoto Y, et al. Immortalization of human nucleus pulposus cells by a recombinant SV40 adenovirus vector: establishment of a novel cell line for the study of human nucleus pulposus cells.Spine. 2004;29(14):
1515-1523.
[14]李连华,翁习生,邱贵兴,等. 2型重组腺相关病毒转染新西兰兔关节软骨细胞的体外研究[J]. 中华医学杂志,2006, 86(21):
1489-1492.
[15]张银刚,郭雄,李天清,等. 髓核内注射骨髓间质干细胞对椎间盘基质的影响[J]. 西安交通大学学报,2007,28(6)675-679.
[16]孙浩林, 李淳德. 原代培养差速贴壁法分离纯化大鼠腰椎间盘髓核细胞[J]. 中国组织工程研究与临床康复,2011,15(46):
8569-8573.
[17]林顺新,徐振华,汪平,等. 兔椎间盘髓核细胞体外培养自然退变的观察[J]. 医学新知杂志,2009,19(3):145-147.
[18]余磊,熊绍虎,戴景兴,等. 兔髓核内细胞的培养及生长曲线的测定[J]. 中华创伤骨科杂志, 2004,6(2): 184-186.
[19]肖剑,赵剑,潘欣,等. 兔腰椎间盘髓核细胞的培养及形态观察[J]. 中国矫形外科杂志, 2001,8(8): 793-795.
[20]张传志,周跃,李长青. 兔髓核细胞体外最佳培养营养条件的探索[J]. 中国矫形外科杂志, 2005,13(12): 1093-1094.
[21]陆森,李国强,王学浩,等.腺相关病毒载体介导的CTLA4Ig表达对大鼠肝移植免疫抑制作用的实验研究[J]. 南京医科大学学报(自然科学版),2005,25(4):224-227.
[22]杨民,马庆军,郭均, 等.重组人骨形态发生蛋白7的腺相关病毒载体的构建[J]. 中国骨与关节损伤杂志,2005,20(7): 458-461.
[23]邰升，苏志雷. 腺相关病毒在肝脏移植应用的研究进展[J]. 世界华人消化杂志,2006,14(22):2155-2158.
[24]黄云剑,赵景宏,杨唐俊, 等.Smad6和Smad7基因腺相关病毒载体的构建及其表达[J].细胞与分子免疫学杂志,2004, 20(3): 274-277.
[25]贺民,鞠延,毛伯镛. 腺相关病毒载体与中枢神经系统疾病的基因治疗[J].华西医学,2000,15(3):379-380.
[26]刘希民. 腺相关病毒载体基础研究及其在造血系统的应用进展[J].白血病•淋巴瘤,2002,11(1):59-61.
[27]李晨,安云庆. 腺相关病毒载体及其在基因治疗中的应用[J].
中国康复理论与实践,2006,12(1):51-52.
[28]王凯,彭建强,陈方平,等. rAAV2-GPⅡb/GPⅢa载体构建和体外表达、功能实验[J].中国实验血液学杂志,2006,14(2):369-374.
[29]徐世平,吴本俨,王孟薇,等. 胃癌相关基因GCRG 213正反义表达重组腺相关病毒载体的构建[J]. 华南国防医学杂志,2007, 21(3):1-5.
[30]Miller DG, Petek LM, Russell DW. Adeno-associated virus vectors integrate at chromosome breakage sites, Nat Genet. 2004;36(7):767-773.　
[31]Iizuka T, Kanzaki S, Mochizuki H, et al. Noninvasive In Vivo Delivery of Transgene via Adeno-Associated Virus into Supporting Cells of the Neonatal Mouse Cochlea. Hum Gene Ther. 2008;19(4):384-390.
[32]丛敏,白艳锋,王萍,等. 腺相关病毒和慢病毒作为小干扰RNA转运载体的比较[J]. 国际外科学杂志,2009,36(9):585-589.
[33]董小岩. 新型腺相关病毒载体及应用研究[J]. 复旦大学,2010.
[34]吕颖慧, 王启钊, 肖卫东, 等. 自身互补型腺相关病毒载体发展趋势[J]. 生物工程学报，2009,25(5): 658-664.
[35]舒静波,刁勇,肖卫东,等. 腺病毒-腺相关病毒嵌合载体的研发趋势[J]. 华侨大学学报(自然科学版),2008,29(2):172-176.